ChemoCentryx News: Berger Montague Investigates Securities Fraud Allegations Against ChemoCentryx, Inc. (CCXI); Lead Plaintiff Deadline is July 6, 2021

Philadelphia, Pennsylvania--(Newsfile Corp. - May 22, 2021) - Berger Montague is investigating securities fraud claims against ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") on behalf of investors who purchased ChemoCentryx securities (NASDAQ: CCXI) between November 26, 2019 and May 3, 2021 (the "Class Period").

If you purchased ChemoCentryx securities during the Class Period, have questions concerning your rights or interests, or would like to discuss Berger Montague's investigation, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Donnell Much at dmuch@bm.net or (215) 875-4667, or complete the form on www.bergermontague.com/chemocentryx.

ChemoCentryx is a biopharmaceutical company focused on developing medications that target inflammatory disorders, autoimmune diseases, and cancer. Its lead drug candidate is avacopan, designed to treat ANCA vasculitis. According to a recent complaint, defendants misrepresented and/or failed to disclose to investors that: (1) the way the Phase III trial study of avacopan was designed made it difficult to interpret the trial data in a clinically meaningful way; (2) the data from the Phase III trial raised serious safety concerns for avacopan; and (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis.

On May 3, 2021, the U.S. Food and Drug Administration ("FDA") published a Briefing Document concerning ChemoCentryx's NDA which raised serious safety concerns with avacopan and which raised issues with the interpretability of the trial data. On this news, the price of ChemoCentryx's common stock fell more than $22 per share - over 45% - in one day, from its May 3, 2021 closing price of $48.82 per share to a May 4, 2021 close of $26.63 per share.

Whistleblowers: Anyone with non-public information regarding ChemoCentryx is encouraged to confidentially assist Berger Montague's investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.

Berger Montague, with offices in Philadelphia, Minneapolis, Washington, D.C., and San Diego, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bm.net

Donnell Much, Associate
Berger Montague
(215) 875-4667
dmuch@bm.net

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/84689